HOME >> BIOLOGY >> NEWS
Staph aureus bacteremia in ESRD patients associated with substantial illness and higher costs

Chicago, Illinois, September 17, 2003 Substantial treatment costs and illness are suffered by end-stage kidney (renal) disease (ESRD) patients who develop Staph aureus blood stream infections (bacteremias), according to new pharmacoeconomic studies presented this week at the 43rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL. Moreover, ESRD patients with Staph aureus bacteremia that are caused by bacteria that are resistant to the antibiotic methicillin (MRSA) are at a higher risk of dying and incur higher treatment costs than patients with bacteremias caused by methicillin sensitive Staph aureus (MSSA). The two studies, sponsored by Nabi Biopharmaceuticals, Inc. (Nasdaq: NABI) and executed by Duke University Medical Center, were presented by investigators from Duke University Medical Center and Duke Clinical Research Institute, Durham, NC.

"Staph aureus is the most common cause of serious hospital-acquired infections, including bloodstream infections, and their increased resistance to many different antibiotics is a growing source of concern in the medical community," said Henrik S. Rasmussen, M.D., Ph.D., Nabi Biopharmaceuticals senior vice president, clinical, medical and regulatory affairs. "Despite its clinical significance, the economic impact of Staph aureus bacteremia has not been fully appreciated. The two studies presented at ICAAC clearly describe the clinical outcomes, associated with health care resource utilization and infection-associated costs of Staph aureus bacteremia among a large group of prospectively identified, hemodialysis-dependent patients. The full data from these studies have been submitted for publication."

"Clearly, these studies point out the tremendous challenges that continue to face healthcare professionals trying to manage Staph aureus bacteremias in ESRD patients," continued Dr. Rasmussen. "These results underscore the need for a new approach such as Nabi Biopharmac
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
17-Sep-2003


Page: 1 2 3 4 5

Related biology news :

1. An aspirin a day keeps Staphylococcus aureus away
2. Discovery of iron-acquisition pathway suggests new treatments for drug-resistant Staph. infections
3. The growing Staphylococcus aureus arsenal
4. Surprising role for Staphs toxic shock toxin
5. Nabi experimental vaccine reduced Staph aureus bloodstream infections by nearly 60 percent
6. Staph bacteria are prolific gene swappers, researchers show
7. Experimental Staph Vaccine Broadly Protective In Animal Studies
8. Nabi reports successful reduction in S. aureus bacteremias at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Trial shows which brain cancer patients benefit from temozolomide
10. Study of flu patients reveals virus outsmarting key drug
11. Decreasing toxins in brains of Alzheimers patients keep cognitive deficits at bay

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/6/2019)... ... 2019 , ... Rigaku Corporation , a global leader ... & Microanalysis 2019 Meeting ( M&M 2019 ), taking place August 4 - ... & Microanalysis Meeting, organized by the Microscopy Society of America, is the world’s ...
(Date:8/1/2019)... CAMBRIDGE, Mass. (PRWEB) , ... August 01, 2019 , ... ... announced by Johannes Fruehauf, MD, PhD, founder and president of BioLabs, which provides premier ... created the CFO role to strengthen our ability to forecast and manage growth,” says ...
(Date:7/26/2019)... ... July 26, 2019 , ... Worldwide Business ... Medical Technologies CEO Phil Deschamps to discuss their potential new treatment option to ... is a neurotech company in the medical device industry that's focused on neurological ...
Breaking Biology News(10 mins):
(Date:7/2/2019)... ... 02, 2019 , ... Leading Regenerative Veterinary Medicine company, VetStem Biopharma , ... The film focuses on regenerative veterinary medicine as a means of improving the ... included in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, ...
(Date:6/18/2019)... Calif. (PRWEB) , ... June 18, 2019 , ... ... an Investigational New Drug (IND) application to the FDA for use of a person’s ... cells as a treatment of osteoarthritis in the knee. This IND is the ...
(Date:6/11/2019)... ... June 10, 2019 , ... Advancements ... an upcoming episode, scheduled to broadcast 4Q/2019. Check your local listings for more ... educate viewers about how its technology facilitates laboratories to improve efficiency and quality ...
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative Medicine ... (PSC) , has announced that their GMP facility for cell production is now ... manufacturing. This is an important milestone for VetStem as it expands into ...
Breaking Biology Technology:
Cached News: